(Q36295897)

13 August 2017

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials (English)

1 reference

13 August 2017

phase I clinical trial

0 references

1

Alexia Iasonos

1 reference

13 August 2017

2

Mrinal Gounder

1 reference

13 August 2017

David R Spriggs

3

1 reference

13 August 2017

John F Gerecitano

4

1 reference

13 August 2017

David M Hyman

5

1 reference

13 August 2017

Sarah Zohar

6

1 reference

13 August 2017

John O'Quigley

7

1 reference

13 August 2017

language of work or name

English

0 references

publication date

23 July 2012

1 reference

13 August 2017

Clinical Cancer Research

1 reference

13 August 2017

18

1 reference

13 August 2017

19

1 reference

13 August 2017

5179-5187

1 reference

Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Dose-escalation models for combination phase I trials in oncology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Dose escalation methods in phase I cancer clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Experimental designs for phase I and phase I/II dose-finding studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Designs for single- or multiple-agent phase I trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Design and analysis of phase I clinical trials

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Personal benefit, or benefiting others? Deciding whether to take part in clinical trials

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Sensitivity of dose-finding studies to observation errors.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Translation of innovative designs into phase I trials.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Non-parametric optimal design in dose finding studies

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Continual reassessment method: a likelihood approach.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Descriptions of benefits and risks in consent forms for phase 1 oncology trials

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

The continual reassessment method for dose-finding studies: a tutorial

21 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463734

Clinical trials data collection: when less is more

5 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22825582

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Development of novel combination therapies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22825582

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Risks and benefits of phase 1 oncology trials, revisited

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22825582

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-12-0726

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

22825582

1 reference